Document:

EX-10.25

 Exhibit 10.25 
 THE OBLIGATIONS DUE UNDER THIS NOTE ARE SECURED BY A STOCK PLEDGE AGREEMENT FOR THE BENEFIT OF LENDER. ADDITIONAL RIGHTS OF LENDER ARE SET FORTH IN THE STOCK PLEDGE AGREEMENT. 

LDR HOLDING CORPORATION 
 NOTE SECURED BY STOCK PLEDGE AGREEMENT 
  

			
	$200,000	  	February 28, 2007
		  	Austin, Texas

 FOR VALUE RECEIVED, Christophe Lavigne (“Maker”) promises to pay to the order of LDR
Holding Corporation, a Delaware corporation (“Lender”), at its corporate offices at 4030 W. Braker Lane, Suite 360, Austin, Texas 78759, the principal sum of Two Hundred Thousand Dollars ($200,000), together with all accrued interest
thereon, upon the terms and conditions specified below. 
 1. Interest. Interest shall be due and payable
quarterly under this Note at the rate of 6% per annum; provided, however, if at any time the Short-Term Applicable Federal Rate is greater than 6%, the interest rate under this Note shall be increased to the Short-Term Applicable Federal Rate.

 2. Principal Due Date. Subject to the accelerated payment provisions of Paragraph 4 of this Note, the principal
balance shall become due and payable in one lump sum on February JL 2014. 
 3. Payment. Payment shall be made in
lawful tender of the United States and shall be applied first to the payment of all accrued and unpaid interest and then to the payment of principal. Prepayment of the principal balance of this Note, together with all accrued and unpaid interest on
the portion of principal so prepaid, may be made in whole or in part at any time without penalty. 
 4. Events of
Acceleration. The entire unpaid principal balance of this Note, together with all accrued and unpaid interest, shall become immediately due and payable prior to the specified due date of this Note upon the occurrence of one or more of the
following events: 
 (a) the failure of Maker to pay any installment of principal or accrued interest under this Note when due
and the continuation of such default for more than sixty (60) days; or 
 (b) the insolvency of Maker, the commission of any
act of bankruptcy by Maker, the execution by Maker of a general assignment for the benefit of creditors, the filing by or against Maker of any petition in bankruptcy or any petition for relief under the provisions of the Federal bankruptcy act or
any other state or federal law for the relief of debtors and the continuation of such petition without dismissal for a period of thirty (30) days or more, the appointment of a receiver or trustee to take possession of any property or assets of
Maker or the attachment of or execution against any property or assets of Maker; or 

 (c) five days prior to the earlier of the date that Lender (i) files a registration
statement pursuant to the Securities Act of 1933, as amended, (ii) has securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or (iii) becomes subject to the reporting requirements of 15(d) of the
Securities Exchange Act of 1934, as amended, provided that if Maker is not then an officer or director of Maker, Lender shall use commercially reasonable efforts (subject in any event to confidentiaility concerns or restrictions that may be imposed
on Lender) to provide Maker with reasonable advance notice of the anticipated or proposed occurrence of either of the foregoing events; provided further, that the failure by Lender to provide such notice in a timely fashion or at all shall not cause
the acceleration of the Note under this section to be delayed or otherwise ineffective or give rise to any liabilty to Maker, nor shall it adversely affect any of Lender’s other rights hereunder; or 

(d) an equity raise by the Lender in which Maker sells up to $200,000 of his stock; or 

(e) the occurrence of any “Event of Default” under the Stock Pledge Agreement dated February 28, 2007 (the “Stock
Pledge Agreement”) securing this Note or any obligation secured thereby. 
 5. Use of Proceeds. Maker shall
use the entire proceeds of this Note solely for the down payment on a principal residence. 
 6. Security. Payment
of this Note shall be secured solely by a pledge of 800,000 shares of Lender’s common stock and the rights to acquire same under the Put-Call Agreement dated April 10, 2006, all of which shall be held by Maker and/or Lender or its designee
pursuant to the Stock Pledge Agreement. 
 7. Representations and Warranties of Maker. 

(a) No Conflict with Other Instruments. The execution, delivery and performance of this Note will not result in any violation of,
be in conflict with, or constitute a default under, with or without the passage of time or the giving of notice: (i) any material provision of any judgment, decree or order to which Maker is a party or by which it is bound or (ii) any
agreement, obligation or commitment to which Maker is a party or by which Maker is bound. 
 (b) Authorization and
Validity. This Note constitutes a legally binding and valid obligation of Maker, enforceable against Maker in accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance, moratorium or other laws affecting creditors’
rights generally and to equitable principles of general applicability. 
 8. Collection. If action is instituted
to collect this Note, Maker promises to pay all costs and expenses (including reasonable attorney fees) incurred in connection with such action. 
 9. Waiver. A waiver of any term of this Note, the Stock Pledge Agreement or of any of the obligations secured thereby must be made in writing and signed by a duly-authorized officer of
Lender (other than Maker) and any such waiver shall be limited to its express terms. 

  
 2 

 No delay by Lender in acting with respect to the terms of this Note or the Stock Pledge
Agreement shall constitute a waiver of any breach, default, or failure of a condition under this Note, the Stock Pledge Agreement or the obligations secured thereby. 
 The Maker waives presentment, demand, notice of dishonor, notice of default or delinquency, notice of acceleration, notice of protest and nonpayment, notice of costs, expenses or losses and interest
thereon, notice of interest on interest and diligence in taking any action to collect any sums owing under this Note or in proceeding against any of the rights or interests in or to properties securing payment of this Note. 

10. Notice. Any notice or demand required or permitted under this Note shall be in writing delivered by means of facsimile
transmission with a copy thereof sent by a nationally-recognized overnight courier service (for next business day delivery), which facsimile and overnight delivery envelope shall be transmitted or addressed, as the case may be, as follows:

 (a) If to the Lender: 
 LDR Holding Corporation 
 4030 W. Braker Lane, Suite 360 

Austin, Texas 78759 
 Fax: (512) 344-3333 
 Attn: Chief Executive Officer 

with a copy (which shall not constitute notice) to: 
 Andrews Kurth LLP 
 111 Congress Avenue, Suite 1700 

Austin, Texas 78701 
 Fax: (512) 320-9292 
 Attn: Carmelo M. Gordian 

(b) If to the Maker: 
 At the address set forth on the Signature Page hereto. 
 Notice given by facsimile
shall be confirmed by appropriate answer back and shall be effective upon actual receipt if received during the recipient’s normal business hours, or at the beginning of the recipient’s next business day after receipt if not received
during the recipient’s normal business hours. All notices by facsimile shall be confirmed promptly after transmission in writing by certified mail or personal delivery. Any party may change any address to which notice is to be given to it by
giving notice as provided above of such change of address. 

  
 3 

 An electronic communication (“Electronic Notice”) shall be deemed written notice
for purposes of this Note if sent with return receipt requested to the electronic mail address specified by the receiving party in a signed writing in a non-electronic form. Electronic Notice shall be deemed received at the time the party sending
Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic Notice may request and shall be entitled to receive notice on paper, in a non-electronic form (“Non-Electronic Notice”) which shall
be sent to the requesting party within ten (10) days of receipt of the written request for Non-Electronic Notice. 
 11.
Conflicting Agreements. In the event of any inconsistencies between the terms of this Note and the terms of any other document related to the loan evidenced by the Note, the terms of this Note shall prevail. 

12. Usury. All agreements between Lender and Maker, whether now existing or hereafter arising and whether written or oral,
are expressly limited so that in no contingency or event whatsoever, whether by acceleration of the maturity of this Note or otherwise, shall the amount paid, or agreed to be paid, to Lender for the use, forbearance or detention of the money to be
loaned hereunder or otherwise, exceed the maximum amount permissible under applicable law. If, from any circumstances whatsoever, fulfillment of any provision of this Note or of any other document evidencing, securing or pertaining to the
indebtedness evidenced hereby, at the time performance of such provision shall be due, shall involve transcending the limit of validity prescribed by law, then ipso facto, the obligation to be fulfilled shall be reduced to the limit of such
validity, and if from any such circumstances Maker shall ever receive anything of value as interest or deemed interest by applicable law under this Note or any other document evidencing, securing or pertaining to the indebtedness evidenced hereby or
otherwise an amount that would exceed the highest lawful rate, such amount that would be excessive interest shall be applied to the reduction of the principal owing under this Note or on account of any other indebtedness of Maker to Lender relating
to this Note, and not to the payment of interest, or if such excessive interest exceeds the unpaid balance of principal of this Note and such other indebtedness, such excess shall be refunded to Lender. In determining whether or not the interest
paid or payable with respect to any indebtedness of Maker to Lender, under any specific contingency, exceeds the highest lawful rate, Lender and Maker shall, to the maximum extent permitted by applicable law, (i) characterize any nonprincipal
payment as an expense, fee or premium rather than as interest, (ii) amortize, prorate, allocate and spread the total amount of interest throughout the full term of such indebtedness so that the actual rate of interest on account of such
indebtedness is uniform throughout the term thereof, and/or (iii) allocate interest between portions of such indebtedness, to the end that no such portion shall bear interest at a rate greater than that permitted by law. The terms and
provisions of this paragraph shall control and supersede every other conflicting provision of all agreements between Lender and Maker. 
 13. Governing Law. THIS NOTE SHALL BE GOVERNED IN ALL RESPECTS BY THE LAWS OF THE STATE OF TEXAS AS SUCH LAWS ARE APPLIED TO AGREEMENTS BETWEEN TEXAS RESIDENTS ENTERED INTO AND TO BE
PERFORMED ENTIRELY WITHIN TEXAS AND WITHOUT REFERENCE TO ITS CONFLICTS OF LAWS PROVISIONS. 
 14. Venue. Courts
within the State of Texas shall have jurisdiction over any and all disputes arising under or pertaining to this Agreement and, to the extent possible, venue for any such disputes shall be in Travis County, Texas. 

  
 4 

 15. Access to Legal Counsel. Both Lender and Maker have been represented by
counsel in connection herewith and have had an opportunity to consult with legal counsel and tax and other advisors in connection with the negotiation of this Note and the matters related hereto. Andrews Kurth LLP has acted solely as legal counsel
to Lender with respect to the preparation and negotiation of this Note and the matters related hereto and has not provided any legal advice to Maker in connection herewith. 
 16. Joint Product. This Note is the joint product of Lender and Maker and each provision hereof has been subject to the mutual consultation, negotiation and agreement of Lender and Maker and
shall not be construed against any party hereto. 
 [Signature Page Follows] 

  
 5 

 IN WITNESS WHEREOF, the undersigned has executed this ote Secured by Stock Pledge Agreement
on and as of the date first above written. 
  

			
	/s/ Christophe Lavigne
	Christophe Lavigne
		
	Address:	 	4030 W Braker Lane
		 	Austin, TX 78759
	Email:	 	christophelavigne@ldrspine.com

 Acknowledged and accepted as of the date first above written: 

 

			
	LDR HOLDING CORPORATION
		
	By:	 	 /s/ Steven I. Whitlock

	Name:	 	Steven I. Whitlock
	Title:	 	SecretaryEX-10.26

 Exhibit 10.26 

 

							
	LDR Médical 	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN CF 01
	 	 	 	Index: 05/29/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 1
/6
	 	 	Implants and Instruments	 	 	 	 

  

	[***]	indicates material that has been omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission. A complete copy of this
agreement, including redacted portions so indicated, has been filed separately with the Securities Exchange Commission. 

 Between 
 CF PLASTIQUES 

ZAC des Bruyères 
 43, rue des Bruyères 
 69330 Pusignan 

And 
  

 
 

 
 LDR MEDICAL 
 4, Rue Gustave Eiffel 
 10430 ROSIÈRES PRES
TROYES 
 [two sets of initials] 
 Contract Ref. (frame): CC FRN 01 Index A 

							
	LDR Médical 	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN CF 01
	 	 	 	Index: 05/29/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 2
/6
	 	 	Implants and Instruments	 	 	 	 

 

 TABLE OF CONTENTS 

 

					
	 1. Purpose
	  	 	3	  
		
	 2. Scope of Application
	  	 	3	  
		
	 2.1 Products
	  	 	3	  
		
	 2.2 Site
	  	 	3	  
		
	 3. Duration
	  	 	3	  
		
	 4. Compliance With Requirements
	  	 	4	  
		
	 5. Deadlines and Penalties for Delay
	  	 	4	  
		
	 6. Responsibility for Design Changes
	  	 	4	  
		
	 7. Non-Conformity
	  	 	4	  
		
	 8. Contractual and Financial Conditions
	  	 	4	  
		
	 8.1 Products
	  	 	4	  
		
	 8.2 Projected LDR Medical needs
	  	 	4	  
		
	 8.3 Batch Size
	  	 	5	  
		
	 8.4 Prices
	  	 	5	  
		
	 8.5 Billing
	  	 	5	  
		
	 8.6 Payment
	  	 	5	  
		
	 9. Packaging and Shipping
	  	 	5	  
		
	 10. Jurisdiction Clause
	  	 	5	  
		
	 11. Termination of Contract
	  	 	5	  
		
	 11.1 Termination
	  	 	5	  
		
	 11.2 Confidentiality
	  	 	6	  

  
 [two sets of
initials] 
 Contract Ref. (frame): CC FRN 01 Index A 

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN CF 01
	 	 	 	Index: 05/29/2012
	

 	 	 	 	AM No.:
	 	 	Implants and Instruments	 	 	 	 Page
 3
/6

  

	1.	Purpose 

 The purpose of
this agreement is to define the conditions of the commercial agreement 
 Between: 

The party of the first part, LDR MEDICAL, a company duly organized and governed by French law, having capital of 215,357.40 euros,
with registered office located at 4 rue Gustave Eiffel, in Troyes, registered with the Troyes Trade and Companies Register under No. 433 924 529, acting on its own behalf as well as for its subsidiaries, Represented by its Deputy Chief
Executive Officer, Mr. Eric Vigneron, Hereinafter referred to as “LDR MEDICAL” 
 And 

The party of the second part, CF PLASTIQUES, a company duly organized and governed by French law, having capital of 100,000 euros,
with registered office located at ZAC des Bruyères 43, rue des Bruyères 69330 Pusignan, registered with the Lyon Trade and Companies Register under No. 343 968 533, Represented by its President and CEO, Mr. Franck Laube,
Hereinafter referred to as “Supplier” 
  

	2.	Scope of Application 

This agreement includes Appendices 1 (signed 05/16/2011 and concerning the number of cages manufactured by volume of peek-optima
material sent), 2 and 3. The terms of this agreement shall prevail over all other previous provisions (with the exception of CC SST CF 01), as well as over the two parties’ general purchase and sale conditions. 

The purpose of this agreement is to set forth the conditions for order placement, manufacture and delivery of the products listed in
Appendix 2 to permit LDR MEDICAL to supply its customers on a timely basis and in the appropriate quantities. 
  

	 	2.1	Products 

 The agreement
applies to the specific components (“products”) listed in Appendix 2 
  

	 	2.2	Site 

 The
“products” shall be delivered to the following address: 
 LDR Médical 

4, Rue Gustave Eiffel 
 10430 ROSIÈRE PRES TROYES 

FRANCE 
  

	3.	Duration 

 This agreement
shall enter into force on the date it is signed by the parties, for a duration of 19 months. Subsequently, each LDR MEDICAL order shall reference it as follows: 
 CC FRN xxxx 01 of yy/yy/yyyy, where x identifies the name of the “Supplier” and y designates the date in dd/mm/yyyy format, serving as the index number for the version of this agreement that has
been approved by the two parties. 

  
 [two sets of
initials] 
 Contract Ref. (frame): CC FRN 01 Index A 

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN CF 01
	 	 	 	Index: 05/29/2012
	

 	 	 	 	AM No.:
	 	 	Implants and Instruments	 	 	 	 Page
 4
/6

  

 Note: the index number shown in the page footer of this document corresponds to
the index number of the original unsigned LDR Médical document. 
 The agreement shall be renewed in the form of an
addendum; said renewal shall occur no later than one month prior to the anniversary date of this agreement. Termination by either party shall be subject to prior notice of nine (9) months. Termination must be communicated by registered letter
with acknowledgement of receipt. 
  

	4.	Compliance with Requirements 

 The “Supplier” agrees to manufacture the “products” ordered by LDR MEDICAL in accordance with the requirements specified in the plans, specification sheets and/or purchase orders.

 The products listed in Appendix 2 shall be delivered to LDR MEDICAL and shall not be subject to systematic monitoring.
Thus, the “Supplier” shall be responsible for ensuring that all internal monitoring to ensure high quality has been performed. 
 An audit shall be carried out every year by LDR MEDICAL at “Supplier’s” facilities to ensure that the entire manufacturing process is in order. 

 

	5.	Deadlines and Penalties for Delay 

 The “Supplier” is required to deliver the “products” within the period specified in its Acknowledgement of Receipt of Order as accepted by LDR Médical. 

The conditions for applying penalties for delay are established in the subcontracting specification sheet CC SST CF 01. 

 

	6.	Responsibility for Design Changes 

 In the event that a product is eliminated, LDR MEDICAL shall notify “Supplier” in writing. 
 LDR MEDICAL agrees to purchase finished products and products in production according to the commitment levels described in Appendix 3. 

In the event that a product is subsequently changed, LDR MEDICAL shall so notify supplier in writing. 

Within forty-eight (48) hours, the “Supplier” must send LDR MEDICAL a statement of production inventory (number of finished
units in inventory, status of items in production) 
 LDR MEDICAL shall issue instructions in accordance with the status of
products in production. 
  

	7.	Non-Conformity 

Non-conforming delivered products shall be handled in accordance with the conditions mentioned in subcontracting specification sheet CC
SST CF 01. 
  

	8.	Contractual and Financial Conditions 

  

	 	8.1	Products 

 All
“products” to be delivered by the “Supplier” are listed in Appendix 2. 
 Order processing shall be
managed in accordance with the conditions specified in subcontracting specifications sheet CC SST CF 01. 

  
 [two sets of
initials] 
 Contract Ref. (frame): CC FRN 01 Index A 

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN CF 01
	 	 	 	Index: 05/29/2012
	

 	 	 	 	AM No.:
	 	 	Implants and Instruments	 	 	 	 Page
 5
/6

  

	 	8.2	Projected LDR Médical Needs 

 A table indicating all of LDR MEDICAL’s quarterly needs for 2012 is listed in Appendix 3. It is understood that the desired delivery dates may be subject to adjustment by LDR MEDICAL depending
upon actual market needs. 
 Furthermore, quantities may be subject to fluctuations of +/- 20%. 

LDR MEDICAL agrees to supply all volumes listed in Appendix 3, attached (minus the 20% variable mentioned above), during the fiscal
year (or no later than three months after its end). 
 Each year, during the final quarter of year N, LDR MEDICAL shall send the
“Supplier” the projected annual orders for year N+1 (with the same quantity range of +/- 20% as defined above). 
  

	 	8.3	Batch Size 

 It has been
agreed that batch size shall be between twenty (20) and seventy (70) units (with no exception for prototypes or demo implants). 
  

	 	8.4	Prices 

 The list of
negotiated prices is as provided in Appendix 2. 
 Prices are firm and applicable for the 2012 year. They will be
renegotiated at year-end and will be included in an addendum for 2013. 
 Prices, expressed in euros, are understood as being net
of taxes, with prepaid shipping and packaging. 
  

	 	8.5	Billing 

For each delivery, an invoice covering all data contained in the order must be prepared and sent to LDR Médical.

  

	 	8.6	Payment 

 LDR
Médical shall pay “Supplier” the amount of each invoice, sixty (60) calendar days after its issuance date, provided that the delivered products are found to be in conformity. In the event of non-compliance, the invoice
settlement time is as detailed in subcontracting specification sheet CC SST CF 01. 
  

	9.	Packaging and Shipping 

“Supplier” shall ship according to batch sizes specified above in Paragraph 9.3. 

Delivery conditions are defined in subcontracting specification sheet CC SST CF 01. 

 

	10.	Jurisdiction Clause 

 Any
dispute concerning this agreement that cannot be settled out of court shall be considered and interpreted in accordance with French law, except with regard to the application of clauses relative to conflicts between laws. In this case, the courts of
Troyes alone shall be deemed competent. 
  

	11.	Termination of Contract 

  

	 	11.1	Termination 

 This
agreement may be terminated at any time by either Party: 
  

	 	a)	in the event of a breach by either Party of any of its obligations and in the event that performance remains possible if the failure to perform persists for fifteen
(15) days from receipt of a registered letter with formal notice to perform; 

  

	 	b)	b) in the event that bankruptcy is filed, payments stop or there is one of the procedures provided for by law regarding court-supervised corporate reorganization or
liquidation. 

  
 [two sets of
initials] 
 Contract Ref. (frame): CC FRN 01 Index A 

							
	LDR Médical 	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN CF 01
	 	 	 	Index: 05/29/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 6
/6
	 	 	Implants and Instruments	 	 	 	 

 

	 	11.2	Confidentiality 

 In the
event that the Contract is terminated due to any reason whatsoever, the confidentiality obligation shall survive for a duration of five (5) years and the “Supplier” agrees to return all information, at the first request of LDR Medical
and not keep any copy of said information on any medium whatsoever. 13. 
 Issued in duplicate in Troyes, May 29, 2012.

  

			
	 Company Name: CF PLASTIQUES
	  	Company Name: LDR MEDICAL
		
	 Commercial stamp
 [stamp]
 CF PLASTIQUES S.A.S.

Capital of 100,000 euros
 ZAC des Bruyères
 43 rue des Bruyères

69330 PUSIGNAN
 Tel. 04 78 31 38 00
 Fax 04 72 05 10 61

APE Code 2229 A – SIRET – RC 343
 968 533 00020
	  	 Commercial stamp
 [stamp:]
 LDR

a passion for innovation
 HOTEL DE BUREAUX 1
 4 rue Gustave Eiffel

10430 Rosières-Près-Troyes
 Tel.: 03 25 82 32 63 - Fax 03 25 82 33 71

		
	Name and title of signatory	  	Name and Title of Signatory
	    [signature] President	  	[signature] CEO
		
	Signature	  	Signature                    \

  
 [two sets of
initials] 
 Contract Ref. (frame): CC FRN 01 Index A 

							
	LDR Médical 	 	 COMMERCIAL SUPPLIER AGREEMENT

  
 APPENDIX 02
	 	  
  

Document  
	 	Ref.: CC FRN CF 01
	 	 	 	 	Index: 05/29/2012
	

 	 	 	 	AM No.:
	 	 	 	 	Page 1/1

  

 PRODUCTS AND PRICES 

 

			
	 PRODUCT
	  	2012 RATE
	 Avenue L Cages
	  	€        [***]/unit
	 ROI C Cages
	  	€        [***]/unit
	 ROI C Lordotic Cages
	  	€        [***]/unit
	 ROI C Bi-Pack Cages
	  	€        [***]/unit
	 MC+ Cages Closed
	  	€        [***]/unit
	 MC+ Cages Bi-Pack
	  	€        [***]/unit
	 MC+ Cages Open
	  	€        [***]/unit

 An end-of year discount shall be granted in late 2012 according to the following conditions: 

 

	 	•	 	 [***]% of sales made for total sales over 12 months greater than €[***] and less than €[***] 

 

	 	•	 	 [***]% of sales made above— 

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

  
 [two sets of
initials] 
 Contract Ref. (frame): CC FRN 01 Index A 

							
	LDR Médical
	 	 COMMERCIAL SUPPLIER AGREEMENT

  
 APPENDIX 01
	 	  
  

Document  
	 	Ref.: CC FRN CF 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 	Page 1/1

  

 2012/2013 PROJECTIONS 

 

					
	 PRODUCT
	  	2012	  	2013
	 Avenue L Cages
	  	[***]	  	[***]
	 ROI C Cages (anatomic and lordotic)
	  	[***]	  	[***]
	 MC+ Cages
	  	[***]	  	[***]

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

  
 [two sets of
initials] 
 Contract Ref. (frame): CC FRN 01 Index A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]